Molecular study of HER2-positive breast cancer subtypes
Treatments studied
Part of Cancer, Skin clinical trials.
This study looks at the genetic details of HER2-positive breast cancer to help find subtypes and improve future treatments. It does not test a new drug but collects information from your tumor tissue to learn more about the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your breast cancer is HER2-positive, meaning it has a specific protein that helps it grow.
- Your cancer is early stage (has not spread to distant organs) or locally advanced (spread to nearby lymph nodes but not to other parts of the body).
- The tumor must be larger than 2 centimeters (about 0.8 inches).
- You have not received any anti-cancer treatment for this breast cancer yet.
- You agree to provide a tissue sample for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This trial tests whether switching between two targeted therapy combinations can help women with HER2-positive advanced breast cancer that has progressed after previous treatments. It aims to find a new effective option for people who have already tried one or two lines of therapy.
This trial tests a combination of targeted therapies and hormone therapy for early-stage breast cancer that is HER2-positive and hormone receptor-positive. The goal is to see if this treatment can help shrink the tumor before surgery.
This trial studies breast cancer tumors to see how specific gene changes and DNA damage patterns relate to the cancer in people with HER2-low disease. It may help doctors better predict which patients could benefit from treatments that target these pathways.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This Phase 2 study looks at how well early breast cancer shrinks with treatment and how that matches with what doctors find after surgery under the microscope. The goal is to learn better ways to predict and assess treatment success.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.